Disease guided optimization of the respiratory delivery of microparticulate formulations

Bibliography

• Sakagami M. In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Adv Drug Deliv Rev 2006;58(9-10):1030-60
   PubMed Web of Science ®Google Scholar
• Sakagami M, Byron PR. Respirable microspheres for inhalation: the potential of manipulating pulmonary disposition for improved therapeutic efficacy. Clin Pharmacokinet 2005;44(3):263-77
   PubMed Web of Science ®Google Scholar
• Videira MA, Gano L, Santos C, Neves M, Almeida AJ. Lymphatic uptake of lipid nanoparticles following endotracheal administration. J Microencapsul 2006;23(8):855-62
   PubMed Web of Science ®Google Scholar
• Hagerman JK, Hancock KE, Klepser ME. Aerosolised antibiotics: a critical appraisal of their use. Expert Opin Drug Deliv 2006;3(1):71-86
   PubMedGoogle Scholar
• Chow AH, TOng HH, Chattopadhyay P, Shekunov BY. Particle engineering for pulmonary drug delivery. Pharm Res 2007;24(3):411-37
   PubMed Web of Science ®Google Scholar
• Geller DE, Pitlick WH, Nardella PA, et al. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 2002;122(1):219-26
   PubMed Web of Science ®Google Scholar
• Cooney GF, Lum BL, Tomaselli M, Fiel SB. Absolute bioavailability and absorption characteristics of aerosolized tobramycin in adults with cystic fibrosis. J Clin Pharmacol 1994;34(3):255-9
   PubMed Web of Science ®Google Scholar
• Touw DJ, Jacobs FA, Brimicombe RW, et al. Pharmacokinetics of aerosolized tobramycin in adult patients with cystic fibrosis. Antimicrob Agents Chemother 1997;41(1):184-7
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay S, Staddon GE, Eastman C, et al. The quantitative distribution of nebulized antibiotic in the lung in cystic fibrosis. Respir Med 1994;88(3):203-11
   PubMed Web of Science ®Google Scholar
• Ilowite JS, G orvoy JD, Smaldone GC. Quantitative deposition of aerosolized gentamicin in cystic fibrosis. Am Rev Respir Dis 1987;136(6):1445-9
   PubMed Web of Science ®Google Scholar
• Poyner EA, Alpar HO, Almeida AJ, et al. A comparative study on the pulmonary delivery of tobramycin encapsulated into liposomes and PLA microspheres following intravenous and endotracheal delivery. J Control Rel 1995;35(1):41-8
   Web of Science ®Google Scholar
• Schreier H, Gonzales-Rothi RJ, Stecenko AA. Pulmonary delivery of liposomes. J Control Release 1993;24:209-23
   Web of Science ®Google Scholar
• Farr SJ, Kellaway IW, Parry-Jones DR, Woolfrey SG. Technetium-99m as a marker of liposomal deposition and clearance in the human lung. Int J Pharm (Kidlington) 1985;26(3):303-16
   Web of Science ®Google Scholar
• Beaulac C, Sachetelli S, Lagace J. Aerosolization of low phase transition temperature liposomal tobramycin as a dry powder in an animal model of chronic pulmonary infection caused by Pseudomonas aeruginosa. J Drug Target 1999;7(1):33-41
   PubMed Web of Science ®Google Scholar
• Sachetelli S, Beaulac C, Riffon R, Lagace J. Evaluation of the pulmonary and systemic immunogenicity of Fluidosomes, a fluid liposomal-tobramycin formulation for the treatment of chronic infections in lungs. Biochim Biophys Acta 1999;1428(2-3):334-40
   PubMed Web of Science ®Google Scholar
• Marier JF, Brazier JL, Lavigne J, Ducharme MP. Liposomal tobramycin against pulmonary infections of Pseudomonas aeruginosa: a pharmacokinetic and efficacy study following single and multiple intratracheal administrations in rats. J Antimicrob Chemother 2003;52(2):247-52
   PubMed Web of Science ®Google Scholar
• Newhouse MT, Hirst PH, Duddu SP, et al. Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers. Chest 2003;124(1):360-6
   PubMed Web of Science ®Google Scholar
• Pilcer G, Sebti T, Amighi K. Formulation and characterization of lipid-coated tobramycin particles for dry powder inhalation. Pharm Res 2006
   PubMedGoogle Scholar
• Pandey, Khuller GK. Antitubercular inhaled therapy: opportunities, progress and challenges. J Antimicrob Chemother 2005;55:430-5
   PubMed Web of Science ®Google Scholar
• De Souza MV. Current status and future prospects for new therapies for pulmonary tuberculosis. Curr Opin Pulm Med 2006;12:167-71
   PubMed Web of Science ®Google Scholar
• Douglas JG, Mcleod MJ. Pharmacokinetic factors in the modern drug treatment of tuberculosis. Clin Pharmacokinet 1999;37(2):127-46
   PubMed Web of Science ®Google Scholar
• Jayaram R, Gaonkar S, Kaur P, et al. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2003;47(7):2118-24
   PubMed Web of Science ®Google Scholar
• Bain DF, Munday DL, Smith A. Modulation of rifampicin release from spray-dried microspheres using combinations of poly-(DL-lactide). J Microencapsul 1999;16(3):369-85
   PubMed Web of Science ®Google Scholar
• Zhang W, Jiang X, Hu J, Fu C. Rifampicin polylactic acid microspheres for lung targeting. J Microencapsul 2000;17(6):785-8
   PubMed Web of Science ®Google Scholar
• O'hara P, Hickey AJ. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization. Pharm Res 2000;17(8):955-61
   PubMed Web of Science ®Google Scholar
• Suarez S, O'Hara P, Kazantseva M, et al. Airways delivery of rifampicin microparticles for the treatment of tuberculosis. J Antimicrob Chemother 2001;48(3):431-4
   PubMed Web of Science ®Google Scholar
• Suarez S, O'Hara P, Kazantseva M, et al. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model. Pharm Res 2001;18(9):1315-9
   PubMed Web of Science ®Google Scholar
• Garcia-Contreras L, Sethuraman V, Kazantseva M, et al. Evaluation of dosing regimen of respirable rifampicin biodegradable microspheres in the treatment of tuberculosis in the guinea pig. J Antimicrob Chemother 2006;58(5):980-6
   PubMed Web of Science ®Google Scholar
• Sharma R, Saxena D, Dwivedi AK, Misra A. Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis. Pharm Res 2001;18(10):1405-10
   PubMed Web of Science ®Google Scholar
• Sharma R, Muttil P, Yadav AB, et al. Uptake of inhalable microparticles affects defence responses of macrophages infected with Mycobacterium tuberculosis H37Ra. J Antimicrob Chemother 2007;59(3):499-506
   PubMed Web of Science ®Google Scholar
• Pandey R, Sharma A, Zahoor A, et al. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother 2003;52(6):981-6
   PubMed Web of Science ®Google Scholar
• Zahoor A, Sharma S, Khuller GK. Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. Int J Antimicrob Agents 2005;26(4):298-303
   PubMed Web of Science ®Google Scholar
• Sharma A, Sharma S, Khuller GK. Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. J Antimicrob Chemother 2004;54(4):761-6
   PubMed Web of Science ®Google Scholar
• Pandey R, Sharma S, Khuller GK. Chemotherapeutic efficacy of nanoparticle encapsulated antitubercular drugs. Drug Deliv 2006;13(4):287-94
   PubMed Web of Science ®Google Scholar
• Kurunov IUN, Ursov IG, Krasnov VA, et al. Effectiveness of liposomal antibacterial drugs in the inhalation therapy of experimental tuberculosis. Probl Tuberk 1995;7(1):38-40
   Google Scholar
• Pandey R, Sharma S, Khuller GK. Nebulization of liposome encapsulated antitubercular drugs in guinea pigs. Int J Antimicrob Agents 2004;24(1):93-4
   PubMed Web of Science ®Google Scholar
• Vyas SP, Kannan ME, Jain S,et al. Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages. Int J Pharm 2004;269(1):37-49
   PubMed Web of Science ®Google Scholar
• Justo OR, Moraes AM. Incorporation of antibiotics in liposomes designed for tuberculosis therapy by inhalation. Drug Deliv 2003;10(3):201-7
   PubMed Web of Science ®Google Scholar
• Pandey R, Khuller GK. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis (Edinb) 2005;85(4):227-34
   PubMed Web of Science ®Google Scholar
• Tsapis N, Bennett D, O'Driscoll K, et al. Direct lung delivery of para-aminosalicylic acid by aerosol particles. Tuberculosis (Edinb) 2003;83(6):379-85
   PubMed Web of Science ®Google Scholar
• Drew. Potential role of aerosolized amphotericin B formulations in the prevention and adjunctive treatment of invasive fungal infections. Int J Antimicrob Agents 2006;27(Suppl 1):36-44
   PubMedGoogle Scholar
• Cocogna CE, White MH, Bernard EM, et al. Efficacy of prophylactic aerosol amphotericin B lipid complex in a rat model of pulmonary aspergillosis. Antimicrob Agents Chemother 1997;41(2):259-61
   PubMed Web of Science ®Google Scholar
• Physicians' Desk Reference (ed.); 2006
   Google Scholar
• Allen SD, Sorensen KN, Nijdl MJ, et al. Prophylactic efficacy of aerosolized liposomal (AmBisome) and non-liposomal (Fungizone) amphotericin B in murine pulmonary aspergillosis. J Antimicrob Chemother 1994;34(6):1001-13
   PubMed Web of Science ®Google Scholar
• Clemons KV, Stevens DA. Comparative efficacies of four amphotericin B formulations – Fungizone, amphotec (Amphocil), AmBisome, and Abelcet – against systemic murine aspergillosis. Antimicrob Agents Chemother 2004;48(3):1047-50
   PubMed Web of Science ®Google Scholar
• Ruijgrok EJ, Vulto AG, Van Etten EW. Aerosol delivery of amphotericin B desoxycholate (Fungizone) and liposomal amphotericin B (AmBisome): aerosol characteristics and in vivo amphotericin B deposition in rats. J Pharm Pharmacol 2000;52(6):619-27
   PubMed Web of Science ®Google Scholar
• Ruijgrok EJ, Vulto AG, Van Etten EW. Efficacy of aerosolized amphotericin B desoxycholate and liposomal amphotericin B in the treatment of invasive pulmonary aspergillosis in severely immunocompromised rats. J Antimicrob Chemother 2001;48(1):89-95
   PubMed Web of Science ®Google Scholar
• Vyas SP, Quraishi S, Gupta S, Jaganathan KS. Aerosolized liposome-based delivery of amphotericin B to alveolar macrophages. Int J Pharm 2005;296(1-2):12-25
   PubMed Web of Science ®Google Scholar
• Lambros MP, Bourne DW, Abbas SA, Johnson DL. Disposition of aerosolized liposomal amphotericin B. J Pharm Sci 1997;86(9):1066-9
   PubMed Web of Science ®Google Scholar
• Niki Y, Bernard EM, Schmitt HJ, et al. Pharmacokinetics of aerosol amphotericin B in rats. Antimicrob Agents Chemother 1990;34(1):29-32
   PubMed Web of Science ®Google Scholar
• Sschwartz, Behre G, Heinemann V, et al. Aerosolized amphotericin B inhalations as prophylaxis of invasive Aspergillus infections during prolong neutropenia: results of a prospective randomized multicenter trial. Blood 1999;93:3654-61
   PubMed Web of Science ®Google Scholar
• Marra F, Partovi N, Wasan KM, et al. Amphotericin B disposition after aerosol inhalation in lung transplant recipients. Ann Pharmacother 2002;36(1):46-51
   PubMed Web of Science ®Google Scholar
• Drew RH, Dodds Ashley E, Benjamin DK Jr, et al. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation 2004;77(2):232-7
   PubMed Web of Science ®Google Scholar
• Palmer SM, Drew RH, Whitehouse JD, et al. Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. Transplantation 2001;72(3):545-8
   PubMed Web of Science ®Google Scholar
• McConville JT, Overhoff KA, Sinswat P, et al. Targeted high lung concentrations of itraconazole using nebulized dispersions in a murine model. Pharm Res 2006;23(5):901-11
   PubMed Web of Science ®Google Scholar
• Vaughn JM, McConville JT, Burgess D, et al. Single dose and multiple dose studies of itraconazole nanoparticles. Eur J Pharm Biopharm 2006;63(2):95-102
   PubMed Web of Science ®Google Scholar
• Edwards DA, Hanes J, Caponetti G, et al. Large porous particles for pulmonary drug delivery. Science 1997;276(5320):1868-71
   PubMed Web of Science ®Google Scholar
• Sakagami M. Insulin disposition in the lung following oral inhalation in humans: a meta-analysis of its pharmacokinetics. Clin Pharmacokinet 2004;43(8):539-52
   PubMed Web of Science ®Google Scholar
• Vanbever R, Mintzes JD, Wang J, et al. Formulation and physical characterization of large porous particles for inhalation. Pharm Res 1999;16(11):1735-42
   PubMed Web of Science ®Google Scholar
• Kawashima Y, Yamamoto H, Takeuchi H, et al. Pulmonary delivery of insulin with nebulized DL-lactide/glycolide copolymer (PLGA) nanospheres to prolong hypoglycemic effect. J Control Rel 1999;62(1-2):279-87
   PubMed Web of Science ®Google Scholar
• Blair J, Coghlan D, Langer E et al. Sustained delivery of insulin via the lung using Solidose technology. Dalby RN, Byron PR, Peart J, Farr SJ, editor. Raleigh, NC: Davis Horwood International Publishing; 2002. p. 411-3
   Google Scholar
• Garcia-Contreras L, Morcol T, Bell SJ, Hickey AJ. Evaluation of novel particles as pulmonary delivery systems for insulin in rats. AAPS PharmSci 2003;5(2):E9
   PubMedGoogle Scholar
• Steiner S, Pfutzner A, Wilson BR, et al. Technosphere/Insulin – proof of concept study with a new insulin formulation for pulmonary delivery. Exp Clin Endocrinol Diabetes 2002;110(1):17-21
   PubMed Web of Science ®Google Scholar
• Surendrakumar K, Martyn GP, Hodgers EC, et al. Sustained release of insulin from sodium hyaluronate based dry powder formulations after pulmonary delivery to beagle dogs. J Control Rel 2003;91(3):385-94
   PubMed Web of Science ®Google Scholar
• Uugaro F, De Rosa G, Miro A, et al. Cyclodextrins in the production of large porous particles: development of dry powders for the sustained release of insulin to the lungs. Eur J Pharm Sci 2006;28(5):423-32
   PubMed Web of Science ®Google Scholar
• Huang YY, Wang CH. Pulmonary delivery of insulin by liposomal carriers. J Control Rel 2006;113(1):9-14
   PubMed Web of Science ®Google Scholar
• Karathanasis E, Bhavane R, Annapragada AV. Triggered release of inhaled insulin from the agglomerated vesicles: pharmacodynamic studies in rats. J Control Rel 2006;113(2):117-27
   PubMed Web of Science ®Google Scholar
• Corcoran TE. Inhaled delivery of aerosolized cyclosporine. Adv Drug Deliv Rev 2006;58(9-10):1119-27
   PubMed Web of Science ®Google Scholar
• Sommerer C, Konstandin M, Dengler T, et al. Pharmacodynamic monitoring of cyclosporine a in renal allograft recipients shows a quantitative relationship between immunosuppression and the occurrence of recurrent infections and malignancies. Transplantation 2006;82(10):1280-5
   PubMed Web of Science ®Google Scholar
• Dowling RD, Zenati M, Burckart GJ, et al. Aerosolized cyclosporine as single-agent immunotherapy in canine lung allografts. Surgery 1990;108(2):198-204; discussion 204-195
   PubMed Web of Science ®Google Scholar
• Keenan RJ, Duncan AJ, Yousem SA, et al. Improved immunosuppression with aerosolized cyclosporine in experimental pulmonary transplantation. Transplantation 1992;53(1):20-5
   PubMed Web of Science ®Google Scholar
• Zenati M, Duncan AJ, Burckart GJ, et al. Immunosuppression with aerosolized cyclosporine for prevention of lung rejection in a rat model. Eur J Cardiothorac Surg 1991;5(5):266-71; discussion 272
   PubMed Web of Science ®Google Scholar
• Koshkina NV, Golunski E, Roberts LE, et al. Cyclosporin A aerosol improves the anticancer effect of paclitaxel aerosol in mice. J Aerosol Med 2004;17(1):7-14
   PubMedGoogle Scholar
• O'Riordan TG, Iacono A, Keenan RJ, et al. Delivery and distribution of aerosolized cyclosporine in lung allograft recipients. Am J Respir Crit Care Med 1995;151(2 Pt 1):516-21
   PubMed Web of Science ®Google Scholar
• Iacono AT, Smaldone GC, Keenan RJ, et al. Dose-related reversal of acute lung rejection by aerosolized cyclosporine. Am J Respir Crit Care Med 1997;155(5):1690-8
   PubMed Web of Science ®Google Scholar
• Knoop C, Vervier I, Thiry P, et al. Cyclosporine pharmacokinetics and dose monitoring after lung transplantation: comparison between cystic fibrosis and other conditions. Transplantation 2003;76(4):683-8
   PubMed Web of Science ®Google Scholar
• Corcoran TE, Smaldone GC, Dauber JH, et al. Preservation of post-transplant lung function with aerosol cyclosporin. Eur Respir J 2004;23(3):378-83
   PubMed Web of Science ®Google Scholar
• Iacono AT, Keenan RJ, Duncan SR, et al. Aerosolized cyclosporine in lung recipients with refractory chronic rejection. Am J Respir Crit Care Med 1996;153(4 Pt 1):1451-5
   PubMed Web of Science ®Google Scholar
• Iacono AT, Corcoran TE, Griffith BP, et al. Aerosol cyclosporin therapy in lung transplant recipients with bronchiolitis obliterans. Eur Respir J 2004;23(3):384-90
   PubMed Web of Science ®Google Scholar
• Lai YL, Mehta RC, Thacker AA, et al. Sustained bronchodilation with isoproterenol poly(glycolide-co-lactide) microspheres. Pharm Res 1993;10(1):119-25
   PubMed Web of Science ®Google Scholar
• Ben-Jebria A, Chen D, Eskew ML, et al. Large porous particles for sustained protection from carbachol-induced bronchoconstriction in guinea pigs. Pharm Res 1999;16(4):555-61
   PubMed Web of Science ®Google Scholar
• Dellamary LA, Tarara TE, Smith DJ, et al. Hollow porous particles in metered dose inhalers. Pharm Res 2000;17(2):168-74
   PubMed Web of Science ®Google Scholar
• Vidgren M, Waldrep JC, Arppe J, et al. A study of 99mtechnetium-labelled beclomethasone dipropionate dilauroylphosphatidylcholine liposome aerosol in normal volunteers. Int J Pharm (Amsterdam) 1995;115(2):209-16
   Web of Science ®Google Scholar
• Huang YC, Yeh MK, Cheng SN, Chiang CH. The characteristics of betamethasone-loaded chitosan microparticles by spray-drying method. J Microencapsul 2003;20(4):459-72
   PubMed Web of Science ®Google Scholar
• Sakagami M, Sakon K, Kinoshita W, Makino Y. Enhanced pulmonary absorption following aerosol administration of mucoadhesive powder microspheres. J Control Rel 2001;77(1-2):117-29
   PubMed Web of Science ®Google Scholar
• Bandi N, Ayalasomayajula SP, Dhanda DS, et al. Intratracheal budesonide-poly(lactide-co-glycolide) microparticles reduce oxidative stress, VEGF expression, and vascular leakage in a benzo(a)pyrene-fed mouse model. J Pharm Pharmacol 2005;57(7):851-60
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Available from: http://www.cancer.org
   Google Scholar
• Kelloff GJ, Hawk ET, Sigman CC. Cancer chemoprevention, Volume 1: Promising Cancer Chemopreventive Agents. (ed.) New Jersey: Humana Press; 2004
   Google Scholar
• Anderson PM, Markovic SN, Sloan JA, et al. Aerosol granulocyte macrophage-colony stimulating factor: a low toxicity, lung-specific biological therapy in patients with lung metastases. Clin Cancer Res 1999;5(9):2316-23
   PubMed Web of Science ®Google Scholar
• Knight V, Kleinerman ES, Waldrep JC, et al. 9-Nitrocamptothecin liposome aerosol treatment of human cancer subcutaneous xenografts and pulmonary cancer metastases in mice. Ann NY Acad Sci 2000;922:151-63
   PubMed Web of Science ®Google Scholar
• Knight V, Koshkina NV, Golunski E, et al. Cyclosporin a aerosol improves the anticancer effect of Paclitaxel aerosol in mice. Trans Am Clin Climatol Assoc 2004;115:395-404
   PubMedGoogle Scholar
• Knight V, Koshkina NV, Waldrep JC, et al. Anticancer effect of 9-nitrocamptothecin liposome aerosol on human cancer xenografts in nude mice. Cancer Chemother Pharmacol 1999;44(3):177-86
   PubMed Web of Science ®Google Scholar
• Hitzman CJ, Wattenberg LW, Wiedmann TS. Pharmacokinetics of 5-fluorouracil in the hamster following inhalation delivery of lipid-coated nanoparticles. J Pharm Sci 2006;95(6):1196-211
   PubMed Web of Science ®Google Scholar
• Anderson PM, Katsanis E, Leonard AS, et al. Increased local antitumor effects of interleukin 2 liposomes in mice with MCA-106 sarcoma pulmonary metastases. Cancer Res 1990;50(6):1853-6
   PubMed Web of Science ®Google Scholar
• Khanna C, Hasz DE, Klausner JS, Anderson PM. Aerosol delivery of interleukin 2 liposomes is nontoxic and biologically effective: canine studies. Clin Cancer Res 1996;2(4):721-34
   PubMed Web of Science ®Google Scholar
• Khanna C, Waldrep JC, Anderson PM, et al. Nebulized interleukin 2 liposomes: aerosol characteristics and biodistribution. J Pharm Pharmacol 1997;49(10):960-71
   PubMed Web of Science ®Google Scholar
• Khanna C, Vail DM. Targeting the lung: preclinical and comparative evaluation of anticancer aerosols in dogs with naturally occurring cancers. Curr Cancer Drug Targets 2003;3(4):265-73
   PubMed Web of Science ®Google Scholar
• Skubitz KM, Anderson PM. Inhalational interleukin-2 liposomes for pulmonary metastases: a Phase I clinical trial. Anticancer Drugs 2000;11(7):555-63
   PubMed Web of Science ®Google Scholar
• Ten RM, Anderson PM, Zein NN, et al. Interleukin-2 liposomes for primary immune deficiency using the aerosol route. Int Immunopharmacol 2002;2(2-3):333-44
   PubMed Web of Science ®Google Scholar
• Koshkina NV, Waldrep JC, Roberts LE, et al. Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model. Clin Cancer Res 2001;7(10):3258-62
   PubMed Web of Science ®Google Scholar
• Hershey AE, Kurzman ID, Forrest LJ, et al. Inhalation chemotherapy for macroscopic primary or metastatic lung tumors: proof of principle using dogs with spontaneously occurring tumors as a model. Clin Cancer Res 1999;5(9):2653-9
   PubMed Web of Science ®Google Scholar
• Koshkina NV, Knight V, Gilbert BE, et al. Improved respiratory delivery of the anticancer drugs, camptothecin and paclitaxel, with 5% CO2-enriched air: pharmacokinetic studies. Cancer Chemother Pharmacol 2001;47(5):451-6
   PubMed Web of Science ®Google Scholar
• Hitzman CJ, Elmquist WF, Wattenberg LW, Wiedmann TS. Development of a respirable, sustained release microcarrier for 5-fluorouracil I: In vitro assessment of liposomes, microspheres, and lipid coated nanoparticles. J Pharm Sci 2006;95(5):1114-26
   PubMed Web of Science ®Google Scholar
• Hitzman CJ, Elmquist WF, Wiedmann TS. Development of a respirable, sustained release microcarrier for 5-fluorouracil II: In vitro and in vivo optimization of lipid coated nanoparticles. J Pharm Sci 2006;95(5):1127-43
   PubMed Web of Science ®Google Scholar
• Hitzman CJ, Wiedmann TS, Dai H, Elmquist WF. Measurement of drug release from microcarriers by microdialysis. J Pharm Sci 2005;94(7):1456-66
   PubMed Web of Science ®Google Scholar
• Tatsumura T, Kroyama S, Tsujimoto M, et al. Further study of nebulisation chemotherapy, a new chemotherapeutic method in the treatment of lung carcinomas: fundamental and clinical. Br J Cancer 1993;68(6):1146-9
   PubMed Web of Science ®Google Scholar
• McIntire GL, Bacon ER, Toner JL, et al. Pulmonary delivery of nanoparticles of insoluble, iodinated CT X-ray contrast agents to lung draining lymph nodes in dogs. J Pharm Sci 1998;87(11):1466-70
   PubMed Web of Science ®Google Scholar
• Grassi C, Ginesu F, Pozzi E, et al. Once-daily tobramycin therapy in lower respiratory tract infections. J Chemother 1995;7(4):371-9
   PubMed Web of Science ®Google Scholar
• Van't Veen A, Gommers D, Verbrugge SJ, et al. Lung clearance of intratracheally instilled 99mTc-tobramycin using pulmonary surfactant as vehicle. Br J Pharmacol 1999;126(5):1091-6
   PubMed Web of Science ®Google Scholar
• Wichert BV, Gonzalez-Rothi RJ, Straub LE, et al. Amikacin liposomes characterization aerosolization and in vitro activity against mycobacterium-avium-intracellulare in alveolar macrophage. Int J Pharm (Kidlington) 1992;78(2-3):227-36
   Web of Science ®Google Scholar
• Schreier H, McNicol KJ, Ausborn M, et al. Pulmonary delivery of amikacin liposomes and acute liposome toxicity in the sheep. Int J Pharm (Amsterdam) 1992;87(1-3):183-93
   Web of Science ®Google Scholar
• Sweeney LG, Wang Z, Loebenberg R, et al. Spray-freeze-dried liposomal ciprofloxacin powder for inhaled aerosol drug delivery. Int J Pharm 2005;305(1-2):180-5
   PubMed Web of Science ®Google Scholar
• McIlleron H, Wash P, Burger A, et al. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob Agents Chemother 2006;50(4):1170-7
   PubMed Web of Science ®Google Scholar
• Deol P, Khuller GK. Lung specific stealth liposomes: stability, biodistribution and toxicity of liposomal antitubercular drugs in mice. Biochim Biophys Acta 1997;1334(2-3):161-72
   PubMed Web of Science ®Google Scholar
• Deol P, Khuller GK, Joshi K. Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice. Antimicrob Agents Chemother 1997;41(6):1211-4
   PubMed Web of Science ®Google Scholar
• Pandey R, Sharma S, Khuller GK. Liposome-based antitubercular drug therapy in a guinea pig model of tuberculosis. Int J Antimicrob Agents 2004;23(4):414-5
   PubMed Web of Science ®Google Scholar
• Liu ZZ, Guo XD, Straub LE, et al. Lipophilic N-acylpyrazinamide derivatives: synthesis, physicochemical characterization, liposome incorporation, and in vitro activity against Mycobacterium avium-intracellulare. Drug Des Discov 1991;8(1):57-67
   PubMedGoogle Scholar
• Kurunov IUN, Nikolin VP, Kaledin VI, et al. Effectiveness of antibacterial preparations incorporated into liposomes in the treatment of experimental tuberculosis. Probl Tuberk 1982;(10):54-8
   PubMedGoogle Scholar
• Kurunov IUN, Kaledin VI, Popova NA, Panteleeva AG. Effectiveness of a liposomal form of rifampicin in the treatment of experimental tuberculosis in mice. Probl Tuberk 1992;1-2:13-5
   PubMedGoogle Scholar
• Dutt M, Khuller GK. Liposomes and PLG microparticles as sustained release antitubercular drug carriers– an in vitro-in vivo study. Int J Antimicrob Agents 2001;18(3):245-52
   PubMed Web of Science ®Google Scholar
• Tomoda K, Kojima S, Kajimoto M, et al. Effects of pulmonary surfactant system on rifampicin release from rifampicin-loaded PLGA microspheres. Colloids Surf B Biointerfaces 2005;45(1):1-6
   PubMed Web of Science ®Google Scholar
• Zhou H, Zhang Y, Biggs DL, et al. Microparticle-based lung delivery of INH decreases INH metabolism and targets alveolar macrophages. J Control Rel 2005;107(2):288-99
   PubMed Web of Science ®Google Scholar
• Liu JH, Zhang LS, Liu ZG, et al. Study on the characteristics of mutation on Mycobacterium tuberculosis rifampicin-resistance gene. Zhonghua Liu Xing Bing Xue Za Zhi 2006;27(11):973-6
   PubMedGoogle Scholar
• Gilbert BE, Wyde PR, Wilson SZ. Aerosolized liposomal amphotericin B for treatment of pulmonary and systemic Cryptococcus neoformans infections in mice. Antimicrob Agents Chemother 1992;36(7):1466-71
   PubMed Web of Science ®Google Scholar
• Gilbert BE, Wyde PR, Lopez-Berestein G, Wilson SZ. Aerosolized amphotericin B-liposomes for treatment of systemic Candida infections in mice. Antimicrob Agents Chemother 1994;38(2):356-9
   PubMed Web of Science ®Google Scholar
• Shah SP, Misra A. Development of liposomal amphotericin B dry powder inhaler formulation. Drug Deliv 2004;11(4):247-53
   PubMed Web of Science ®Google Scholar
• Gilbert BE. Liposomal aerosols in the management of pulmonary infections. J Aerosol Med 1996;9(1):111-22
   PubMedGoogle Scholar
• Kim JC, Kim JD. Preparation by spray drying of amphotericin B-phospholipid composite particles and their anticellular activity. Drug Deliv 2001;8(3):143-7
   PubMed Web of Science ®Google Scholar
• Corcoran TE, Venkataramanan R, Mihelc KM, et al. Aerosol deposition of lipid complex amphotericin-B (Abelcet) in lung transplant recipients. Am J Transplant 2006;6(11):2765-73
   PubMed Web of Science ®Google Scholar
• Clemons KV, Parmar R, Martinez M, Stevens DA. Efficacy of Abelcet alone, or in combination therapy, against experimental central nervous system aspergillosis. J Antimicrob Chemother 2006;58(2):466-9
   PubMed Web of Science ®Google Scholar
• Liu FY, Shao Z, Koldsig DO, Mitra AK. Pulmonary delivery of free and liposomal insulin. Pharm Res 1993;10(2):228-32
   PubMed Web of Science ®Google Scholar
• VanBever R, Ben-Jebria A, Mintzes JD, et al. Sustained release of insulin from insoluble inhaled particles. Drug Dev Res 1999;48(4):178-85
   Web of Science ®Google Scholar
• Gilbert BE, Knight C, Alvarez FG, et al. Tolerance of volunteers to cyclosporine A-dilauroylphosphatidylcholine liposome aerosol. Am J Respir Crit Care Med 1997;156(6):1789-93
   PubMed Web of Science ®Google Scholar
• Waldrep JC, Scherer PW, Keyhani K, Knight V. Cyclosporin A liposome aerosol: particle size and calculated respiratory deposition. Int J Pharm (Amsterdam) 1993;97(1-3):205-12
   Web of Science ®Google Scholar
• Waldrep JC, Arppe J, Jansa KA, Knight V. High dose cyclosporin A and budesonide-liposome aerosols. Int J Pharm (Amsterdam) 1997;152(1):27-36
   Web of Science ®Google Scholar
• Kawashima Y, Serigano T, Hino T, et al. Surface-modified antiasthmatic dry powder aerosols inhaled intratracheally reduce the pharmacologically effective dose. Pharm Res 1998;15(11):1753-9
   PubMed Web of Science ®Google Scholar
• Pettenazzo A, Jobe A, Ikegami M, et al. Clearance of phosphatidylcholine and cholesterol from liposomes, liposomes loaded with metaproterenol, and rabbit surfactant from adult rabbit lungs. Am Rev Respir Dis 1989;139(3):752-8
   PubMed Web of Science ®Google Scholar
• McCalden TA, Abra RA, Mihalko PJ. Bronchodilator effects of some liposome formulations of metaproterenol sulfate in guinea pigs. Proc West Pharmacol Soc 1988;31:129-32
   PubMedGoogle Scholar
• McCalden TA, Porter J, Kamarei A. Aerosol delivery of liposome metaproterenol sulfate. Proc West Pharmacol Soc 1990;33:171-3
   PubMedGoogle Scholar
• McCalden TA, Radhakrishnan R. A comparative study of the bronchodilator effect and duration of action of liposome encapsulated beta-2 adrenergic agonists in the guinea-pig. Pulm Pharmacol 1991;4(3):140-5
   PubMedGoogle Scholar
• Taylor KM, Taylor G, Kellaway IW, Stevens J. The influence of liposomal encapsulation on sodium cromoglycate pharmacokinetics in man. Pharm Res 1989;6(7):633-6
   PubMed Web of Science ®Google Scholar
• Fielding RM, Abra RM. Factors affecting the release rate of terbutaline from liposome formulations after intratracheal instillation in the guinea pig. Pharm Res 1992;9(2):220-3
   PubMed Web of Science ®Google Scholar
• Sebti T, Pilcer G, Van Gansbeke B, et al. Pharmacoscintigraphic evaluation of lipid dry powder budesonide formulations for inhalation. Eur J Pharm Biopharm 2006;64(1):26-32
   PubMed Web of Science ®Google Scholar
• Waldrep JC, Keyhani K, Black M, Knight V. Operating characteristics of 18 different continuous-flow jet nebulizers with beclomethasone dipropionate liposome aerosol. Chest 1994;105(1):106-10
   PubMed Web of Science ®Google Scholar
• Waldrep JC, Gilbert BE, Knight CM, et al. Pulmonary delivery of beclomethasone liposome aerosol in volunteers. Tolerance and safety. Chest 1997;111(2):316-23
   PubMed Web of Science ®Google Scholar
• Forsgren PE, Modig JA, Dahlback CM, Axelsson BI. Prophylactic treatment with an aerosolized corticosteroid liposome in a porcine model of early ARDS induced by endotoxaemia. Acta Chir Scand 1990;156(6-7):423-31
   PubMedGoogle Scholar
• McCullough HN, Juliano RL. Organ-selective action of an antitumor drug: pharmacologic studies of liposome-encapsulated beta-cytosine arabinoside administered via the respiratory system of the rat. J Natl Cancer Inst 1979;63(3):727-31
   PubMed Web of Science ®Google Scholar
• Juliano RL, McCullough HN. Controlled delivery of an antitumor drug: localized action of liposome encapsulated cytosine arabinoside administered via the respiratory system. J Pharmacol Exp Ther 1980;214(2):381-7
   PubMed Web of Science ®Google Scholar
• Sone S, Tachibana K, Shono M, et al. Potential value of liposomes containing muramyl dipeptide for augmenting the tumoricidal activity of human alveolar macrophages. J Biol Response Mod 1984;3(2):185-94
   PubMedGoogle Scholar
• Lorenz J, Wilhelm K, Kessler M, et al. Phase I trial of inhaled natural interleukin 2 for treatment of pulmonary malignancy: toxicity, pharmacokinetics, and biological effects. Clin Cancer Res 1996;2(7):1115-22
   PubMed Web of Science ®Google Scholar
• Khanna C, Anderson PM, Hasz DE, et al. Interleukin-2 liposome inhalation therapy is safe and effective for dogs with spontaneous pulmonary metastases. Cancer 1997;79(7):1409-21
   PubMed Web of Science ®Google Scholar
• Rao JN, Clark SC, Aali S, et al. Improvements in lung compliance after pulmonary transplantation: correlation with interleukin 8 expression. Eur J Cardiothorac Surg 2003;23(4):497-502
   PubMed Web of Science ®Google Scholar
• Rohrmann K, Schleypen J, Adam C, et al. Complete remission of pulmonary metastasis from renal cell carcinoma through inhalation therapy with Interleukin-2 after unsuccessful systemic immunochemotherapy. Urologe A 2004;43(10):1271-4
   PubMedGoogle Scholar
• Koshkina NV, Gilbert BE, Waldrep JC, et al. Distribution of camptothecin after delivery as a liposome aerosol or following intramuscular injection in mice. Cancer Chemother Pharmacol 1999;44(3):187-92
   PubMed Web of Science ®Google Scholar
• Verschraegen CF, Gilbert BE, Huaringa AJ, et al. Feasibility, Phase I, and pharmacological study of aerosolized liposomal 9-nitro-20(S)-camptothecin in patients with advanced malignancies in the lungs. Ann NY Acad Sci 2000;922:352-4
   PubMed Web of Science ®Google Scholar
• Koshkina NV, Waldrep JC, Knight V. Camptothecins and lung cancer: improved delivery systems by aerosol. Curr Cancer Drug Targets 2003;3(4):251-64
   PubMed Web of Science ®Google Scholar
• Lawson KA, Anderson K, Snyder RM, et al. Novel vitamin E analogue and 9-nitro-camptothecin administered as liposome aerosols decrease syngeneic mouse mammary tumor burden and inhibit metastasis. Cancer Chemother Pharmacol 2004;54(5):421-31
   PubMed Web of Science ®Google Scholar
• Parthasarathy R, Gilbert B, Mehta K. Aerosol delivery of liposomal all-trans-retinoic acid to the lungs. Cancer Chemother Pharmacol 1999;43(4):277-83
   PubMed Web of Science ®Google Scholar
• Wang Z, Chen HT, Roa W, Finlay W. Farnesol for aerosol inhalation: nebulization and activity against human lung cancer cells. J Pharm Pharm Sci 2003;6(1):95-100
   PubMed Web of Science ®Google Scholar
• Jin H, Kim TH, Hwang SK, et al. Aerosol delivery of urocanic acid-modified chitosan/programmed cell death 4 complex regulated apoptosis, cell cycle, and angiogenesis in lungs of K-ras null mice. Mol Cancer Ther 2006;5(4):1041-9
   PubMed Web of Science ®Google Scholar
• Azarmi S, Tao X, Chen H, et al. Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles. Int J Pharm 2006;319(1-2):155-61
   PubMed Web of Science ®Google Scholar
• Tian Y, Klegerman ME, Hickey AJ. Evaluation of microparticles containing doxorubicin suitable for aerosol delivery to the lungs. PDA J Pharm Sci Technol 2004;58(5):266-75
   PubMedGoogle Scholar
• Wittgen BP, Kunst PW, Van Der Born K, et al. Phase I study of aerosolized SLIT cisplatin in the treatment of patients with carcinoma of the lung. Clin Cancer Res 2007;13(8):2414-21
   PubMed Web of Science ®Google Scholar
• Halme M, Maasilta P, Repo H, et al. Inhaled recombinant interferon gamma in patients with lung cancer: pharmacokinetics and effects on chemiluminescence responses of alveolar macrophages and peripheral blood neutrophils and monocytes. Int J Radiat Oncol Biol Phys 1995;31(1):93-101
   PubMed Web of Science ®Google Scholar
• Barker SA, Taylor KMG, Short MD. The deposition and clearance of liposome entrapped 99mTc-DTPA ion the human respiratory tract. Int J Pharm (Amsterdam) 1994;102(1-3):159-65
   Web of Science ®Google Scholar
• Gervelas C, Serandour AL, Geiger S, et al. Direct lung delivery of a dry powder formulation of DTPA with improved aerosolization properties: effect on lung and systemic decorporation of plutonium. J Control Rel 2007;118(1):78-86
   PubMed Web of Science ®Google Scholar
• Wang J, Ben-Jebria A, Edwards DA. Inhalation of estradiol for sustained systemic delivery. J Aerosol Med 1999;12(1):27-36
   PubMedGoogle Scholar
• Morimoto K, Katsumata H, Yabuta T, et al. Gelatin microspheres as a pulmonary delivery system: evaluation of salmon calcitonin absorption. J Pharm Pharmacol 2000;52(6):611-7
   PubMed Web of Science ®Google Scholar
• Koushik K, Dhanda DS, Cheruvu NP, Kompella UB. Pulmonary delivery of deslorelin: large-porous PLGA particles and HPbetaCD complexes. Pharm Res 2004;21(7):1119-26
   PubMed Web of Science ®Google Scholar
• Bot AI, Tarara TE, Smith DJ, et al. Novel lipid-based hollow-porous microparticles as a platform for immunoglobulin delivery to the respiratory tract. Pharm Res 2000;17(3):275-83
   PubMed Web of Science ®Google Scholar
• Bot AI, Smith DJ, Bot S, et al. Receptor-mediated targeting of spray-dried lipid particles coformulated with immunoglobulin and loaded with a prototype vaccine. Pharm Res 2001;18(7):971-9
   PubMed Web of Science ®Google Scholar
• Dellamary L, Smith DJ, Bloom A, et al. Rational design of solid aerosols for immunoglobulin delivery by modulation of aerodynamic and release characteristics. J Control Rel 2004;95(3):489-500
   PubMed Web of Science ®Google Scholar
• Wyde PR, Wilson SZ, Kramer MJ, et al. Pulmonary deposition and clearance of aerosolized interferon. Antimicrob Agents Chemother 1984;25(6):729-34
   PubMed Web of Science ®Google Scholar
• Buckley BJ, Tanswell AK, Freeman BA. Liposome-mediated augmentation of catalase in alveolar type II cells protects against H2O2 injury. J Appl Physiol 1987;63(1):359-67
   PubMed Web of Science ®Google Scholar
• Jurima-Romet M, Barber RF, Demeester J, Shek PN. Distribution studies of liposome-encapsulated glutathione administered to the lung. Int J Pharm (Kidlington) 1990;63(3):227-36
   Web of Science ®Google Scholar
• Jurima-Romet M, Shek PN. Lung uptake of liposome-entrapped glutathione after intratracheal administration. J Pharm Pharmacol 1991;43(1):6-10
   PubMed Web of Science ®Google Scholar
• Debs RJ, Straubinger RM, Brunette EN, et al. Selective enhancement of pentamidine uptake in the lung by aerosolization and delivery in liposomes. Am Rev Respir Dis 1987;135(3):731-7
   PubMed Web of Science ®Google Scholar
• Wyde PR, Six HR, Wilson SZ, et al. Activity against rhinoviruses, toxicity, and delivery in aerosol of enviroxime in liposomes. Antimicrob Agents Chemother 1988;32(6):890-5
   PubMed Web of Science ®Google Scholar